来那度胺联合R-CHOP治疗DLBCL改善ALC/AMC比值的研究进展  

Research progress on the improvement of ALC/AMC ratio in DLBCL treated with lenalidomide combined with R-CHOP

作　　者：侯洋洋 刘爱春[1] HOU Yangyang;LIU Aichun(Department of Hematology and Lymphology,Affiliated Tumor Hospital of Harbin Medical University,Heilongjiang Harbin 150081,China)

机构地区：[1]哈尔滨医科大学附属肿瘤医院血液淋巴内科,黑龙江哈尔滨150081

出　　处：《现代肿瘤医学》2023年第13期2519-2522,共4页Journal of Modern Oncology

摘　　要：弥漫大B细胞淋巴瘤(diffuse large B-cell lymphomas,DLBCL)是非霍奇金淋巴瘤的主要亚型。DLBCL在临床表现、基因表达、治疗反应及预后方面均存在差异,外周血绝对淋巴细胞(ALC)/单核细胞(AMC)比值(ALC/AMC)作为宿主免疫和肿瘤微环境的替代指标,是预测DLBCL患者临床疗效的生物标志物。来那度胺是一种免疫调节药物,对DLBCL患者有效,对肿瘤微环境及宿主免疫反应有多种作用机制。来那度胺联合标准R-CHOP治疗以前未经治疗的DLBCL患者,似乎克服了单用R-CHOP治疗患者ALC/AMC比值的不良预后价值,本文对这一观点进行综述。Diffuse large B-cell lymphoma(DLBCL)is the major subtype of non-Hodgkin lymphoma.DLBCL is different in clinical manifestation,gene expression,treatment response and prognosis.The ratio of peripheral lymphocyte cells to monocytes(ALC/AMC)is a surrogate index for host immunity and tumor microenvironment,it is a biomarker for predicting the clinical outcome of patients with DLBCL.Lenalidomide is an immunomodulatory drug that is effective in DLBCL patients and has multiple mechanisms of action on tumor microenvironment and host immune response.In this review,the adverse prognostic value of ALC/AMC ratio appears to be overcome by lenalidomide combined with standard R-CHOP in previously untreated DLBCL patients.

关 键 词：弥漫大B细胞淋巴瘤 来那度胺 淋巴细胞/单核细胞 预后 

分 类 号：R733.4[医药卫生—肿瘤]